Ixabepilone, a novel epothilone analog in the treatment of breast cancer

Expert Opin Investig Drugs. 2008 Apr;17(4):593-9. doi: 10.1517/13543784.17.4.593.


Background: Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing cell death. Ixabepilone (BMS-247550, Ixempra) is an epothilone analog that optimizes the properties naturally observed with epothilone B.

Objective: To provide an overview of the results achieved by ixabepilone in metastatic breast cancer.

Methods: A PubMed search was performed to provide an extensive review of all published data on ixabepilone, in addition to all data reported from international congresses, from 2003 to 2007.

Results/conclusion: There is a clear need for new agents active against resistant metastatic breast cancer and ixabepilone might be a welcome new compound in this situation.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cell Death / drug effects
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation, Preclinical
  • Epothilones / adverse effects
  • Epothilones / pharmacokinetics
  • Epothilones / therapeutic use*
  • Female
  • Humans
  • Molecular Structure
  • Neoplasm Metastasis
  • Treatment Outcome
  • Tubulin Modulators / adverse effects
  • Tubulin Modulators / pharmacokinetics
  • Tubulin Modulators / therapeutic use*


  • Antineoplastic Agents
  • Epothilones
  • Tubulin Modulators
  • ixabepilone